Forecast

There is no analyst data available for this company.

News Go to news feed

Sandoz seeks preliminary approval in US for $400 million settlement

US states have asked a federal court in Connecticut for preliminary approval of a settlement with Sandoz over alleged price‑fixing for generics. The agreement covers 43 US jurisdictions and provides for total payments of $400 million over seven years, about $320.6 million as settlement principal and $79.4 million in interest. Sandoz and Fougera Pharmaceuticals, a subsidiary acquired in 2012, are accused of fixing prices and dividing markets; Sandoz denies the allegations. The first payment is due after final court approval, and no decision date has yet been set. » More on finanzen.net
Sandoz opens production center for biosimilar active ingredients in Lendava

Sandoz has opened a new production center for biosimilar active ingredients in Lendava, Slovenia, to increase capacity and flexibility within its European production network. By expanding capacity, the company aims to have more than 100 biosimilars in its portfolio over the long term. » More on finanzen.net
Sandoz gets approval for semaglutide generic in Canada, competition for Novo Nordisk

Sandoz has received market approval in Canada for a generic version of the diabetes drug semaglutide, authorized as a weekly injection for adult patients with type 2 diabetes. The Canadian market for GLP‑1 drugs is estimated at around $2.6 billion and includes roughly 12 million semaglutide injection pens annually. Sandoz also reports approval in Brazil and is studying a tirzepatide generic in the US; the Canadian approval does not affect its 2026 guidance. » More on finanzen.net

Historical dividends Dividends

All dividend metrics All metrics

In 2026, Sandoz has already paid €0.87 in dividends. The last payout was in April.

Financials

In the last quarter, Sandoz had revenue of €4.94bn and net profit of €93.42m

(EUR)	June 2026	YoY
Revenue	4.94bn	-
Gross profit	2.3bn	-
Net profit	93.42m	-
EBITDA	959.02m	-

Fundamentals

Metric	Value
Market capitalization	€32.74bn
Number of shares	432.01m
52-week high/low	€81.11 - €25.13
Dividend yield	1.18%
Dividends TTM	€0.87
Beta	0.49
P/E ratio	56.96
PEG ratio	0.31
P/B ratio	4.09
P/S ratio	3.18

Company profile

Die Sandoz Group AG entwickelt, produziert und vermarktet weltweit generische Arzneimittel und Biosimilars. Sie entwickelt, produziert und vermarktet fertige Darreichungsformen von Arzneimitteln mit kleinen Molekülen für Dritte. Darüber hinaus bietet das Unternehmen Produkte auf Protein- oder anderer Biotechnologiebasis, einschließlich Biosimilars, sowie biotechnologische Produktionsdienstleistungen und Antiinfektiva, wie pharmazeutische Wirkstoffe und Zwischenprodukte, vor allem Antibiotika, an. Das Unternehmen wurde 1886 gegründet und hat seinen Hauptsitz in Rotkreuz, Schweiz.